Effect of Curcumin on Iron Metabolism in Healthy Volunteer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01489592

Acronym

CURHEP

Enrollment

Registered

2011-12-09

Start date

2011-10-31

Completion date

2012-03-31

Last updated

2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

The purpose of this study is to determine the impact of curcumin, administrated orally, on iron metabolism in healthy volunteers. Iron metabolism will be describe by hepcidin expression that the investigators observed in vitro and serum hepcidin levels.

Interventions

DRUGcurcuma longa

oral administration of 6 grams of curcumin

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* Body mass index between 18 et 25 Kg/m² * Non smoker * No swallowing disorders * Normal clinical exam * Normal ECG * Normal values for routine biological tests : serum iron, transferrin saturation,, hemogram ferritin, C Reactive Protein, AST, ALT, HDL and LDL cholesterol, triglycerides * No C282Y mutation within the HFE gene * Affiliation to social security * Written informed consent obtained

Exclusion criteria

* Chronic or evolutive disease * Infection during the 7 days before each sequence * Drug or alcohol (\>30g) abuse * Current treatment * Known food allergy * stay at altitude (\> 1500m) in 2 months * Positive serology for hepatitis B or C virus or HIV. * Transfusion or blood donation during the last three months. * Exclusion period on the healthy volunteer National File.

Design outcomes

Primary

Measure	Time frame
Maximal variation of serum hepcidin level after oral administration of curcumin	within 48 hours after administration of curcumin

Secondary

Measure	Time frame	Description
Plasmatic iron bioavailability	30min, 1H, 2H, 3H, 4H, 6H, 8H, 12H, 24H et 48H	Iron, ferritin, transferrin, transferrin saturation
Evaluation of the inhibitory activity of volunteers's serum on hepcidin expression by hepatocytes	30min, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h	In vitro: * the coculture model that we previously developed to analyze endogenous hepcidin expression, and * human hepatic cells line (HepG2) stimulated or not by IL-6 which governs the STAT3 pathway, transfected with gene reporter constructs containing hepcidin promoter.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026